Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting

Biomaterials

Volumn 32, Issue 20, 2011, Pages 4574-4583

  Thomann, Jean Sébastien ^a   Heurtault, Béatrice ^a   Weidner, Steffen ^a   Brayé, Mélanie ^b   Beyrath, Julien ^b   Fournel, Sylvie ^b   Schuber, Francis ^a   Frisch, Benoît ^a  

^a Faculté de Pharmacie   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cancer vaccine; Dendritic cell targeting; Liposome; Peptide based vaccine; TLR ligands

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTI-TUMORS; ANTIGEN PRESENTING CELLS; CANCER VACCINE; CYTOTOXIC; CYTOTOXIC T LYMPHOCYTES; DENDRITIC CELLS; EPITOPE PEPTIDE; IMMUNE RESPONSE; MANNOSE RECEPTORS; MANNOSYLATED LIPOSOMES; PEPTIDE EPITOPES; POTENTIAL SYNERGIES; TARGETING MOLECULES; THERAPEUTIC EFFICIENCY; TLR LIGANDS; TUMOR CELLS;

ANTIGENS; CELLS; DISEASES; IMMUNOLOGY; LIPOSOMES; PEPTIDES; PHOSPHOLIPIDS; PHYSIOLOGICAL MODELS; TUMORS; VACCINES;

LIGANDS;

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; LIPOSOME; MANNOSE RECEPTOR; PEPTIDE VACCINE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; EPITOPES; FEMALE; LECTINS, C-TYPE; LIPOSOMES; MANNOSE-BINDING LECTINS; MATERIALS TESTING; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEOPLASMS; PEPTIDES; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS;

MUS;

EID: 79955523586     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.03.015     Document Type: Article

References (41)

1. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997, 18(4):175-182.
2. Van den Eynde B., Gaugler B., van der Bruggen P., Coulie P., Brichard V., Boon T. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines. Biochem Soc Trans 1995, 23(3):681-686.
3. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009, 9(1):57-63.
4. Seya T., Akazawa T., Uehori J., Matsumoto M., Azuma I., Toyoshima K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003, 23(6a):4369-4376.
5. Melief C.J. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur J Immunol 2003, 33(10):2645-2654.
6. Renno T., Lebecque S., Renard N., Saeland S., Vicari A. What's new in the field of cancer vaccines?. Cell Mol Life Sci 2003, 60(7):1296-1310.
7. Lahiri A., Das P., Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008, 26(52):6777-6783.
8. Steinman R.M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008, 29(3):319-324.
9. Fernandes I., Frisch B., Muller S., Schuber F. Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen. Mol Immunol 1997, 34(8-9):569-576.
10. Takeda K., Takeuchi O., Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 2002, 8(6):459-463.
11. Hertz C.J., Kiertscher S.M., Godowski P.J., Bouis D.A., Norgard M.V., Roth M.D., et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001, 166(4):2444-2450.
12. Wiesmuller K.H., Bessler W.G., Jung G. Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response. Int J Pept Protein Res 1992, 40(3-4):255-260.
13. Roth A., Rohrbach F., Weth R., Frisch B., Schuber F., Wels W.S. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 p.ptide-based vaccination construct. Br J Cancer 2005, 92(8):1421-1429.
14. Taylor P.R., Gordon S., Martinez-Pomares L. The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol 2005, 26(2):104-110.
15. Nagata Y., Furugen R., Hiasa A., Ikeda H., Ohta N., Furukawa K., et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997, 159(3):1336-1343.
16. Espuelas S., Haller P., Schuber F., Frisch B. Synthesis of an amphiphilic tetraantennary mannosyl conjugate and incorporation into liposome carriers. Bioorg Med Chem Lett 2003, 13(15):2557-2560.
17. Heurtault B., Gentine P., Thomann J.S., Baehr C., Frisch B., Pons F. Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity. Pharm Res 2009, 26(2):276-285.
18. Roth A., Espuelas S., Thumann C., Frisch B., Schuber F. Synthesis of thiol-reactive lipopeptide adjuvants. incorporation into liposomes and study of their mitogenic effect on mouse splenocytes. Bioconjug Chem 2004, 15(3):541-553.
19. Boeckler C., Dautel D., Schelte P., Frisch B., Wachsmann D., Klein J.P., et al. Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes. Eur J Immunol 1999, 29(7):2297-2308.
20. Monsigny M., Petit C., Roche A.C. Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod. Anal Biochem 1988, 175(2):525-530.
21. Maurer-Gebhard M., Schmidt M., Azemar M., Altenschmidt U., Stocklin E., Wels W., et al. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 1998, 58(12):2661-2666.
22. Hauschildt S., Scheipers P., Bessler W.G. Lipopolysaccharide-induced change of ADP-ribosylation of a cytosolic protein in bone-marrow-derived macrophages. Biochem J 1994, 297(Pt 1):17-20.
23. Prass W., Ringsdorf H., Bessler W., Wiesmuller K.H., Jung G. Lipopeptides of the N-terminus of Escherichia coli lipoprotein: synthesis, mitogenicity and properties in monolayer experiments. Biochim Biophys Acta 1987, 900(1):116-128.
24. Reitermann A., Metzger J., Wesmüller R., Jung G., Bessler W.G. Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten. Biol Chem Hoppe Seyler 1989, 370(4):343-352.
25. Muhlradt P.F., Kiess M., Meyer H., Sussmuth R., Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997, 185(11):1951-1958.
26. Okusawa T., Fujita M., Nakamura J., Into T., Yasuda M., Yoshimura A., et al. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun 2004, 72(3):1657-1665.
27. Espuelas S., Thumann C., Heurtault B., Schuber F., Frisch B. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjug Chem 2008, 19(12):2385-2393.
28. Disis M.L., Goodell V., Schiffman K., Knutson K.L. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 2004, 24(5):571-578.
29. Harada M., Matsueda S., Yao A., Noguchi M., Itoh K. Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient. J Immunother 2005, 28(4):368-375.
30. Alving C.R., Koulchin V., Glenn G.M., Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 1995, 145:5-31.
31. Alving C.R., Wassef N.M. Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation. AIDS Res Hum Retroviruses 1994, 10(Suppl. 2):S91-S94.
32. Bergers J.J., ten Hagen T.L., van Etten E.W., Bakker-Woudenberg I.A. Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharm World Sci 1995, 17(1):1-11.
33. Heurtault B., Thomann J.S., Jedrzejewska J., Wels W.S., Schuber F., Frisch B. Liposome-based systems for anti-tumor vaccination: influence of lipopeptide adjuvants. J Liposome Res 2006, 16(3):205-213.
34. Said Hassane F., Phalipon A., Tanguy M., Guerreiro C., Belot F., Frisch B., et al. Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen. Vaccine 2009, 27(39):5419-5426.
35. White K.L., Rades T., Furneaux R.H., Tyler P.C., Hook S. Mannosylated liposomes as antigen delivery vehicles for targeting to dendritic cells. J Pharm Pharmacol 2006, 58(6):729-737.
36. Murphy G.P., Hrushesky W.J. A murine renal cell carcinoma. J Natl Cancer Inst 1973, 50(4):1013-1025.
37. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004, 101(43):15440-15445.
38. Omueti K.O., Beyer J.M., Johnson C.M., Lyle E.A., Tapping R.I. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem 2005, 280(44):36616-36625.
39. Metzger J.W., Beck-Sickinger A.G., Loleit M., Eckert M., Bessler W.G., Jung G. Synthetic S-(2,3-dihydroxypropyl)-cysteinyl peptides derived from the N-terminus of the cytochrome subunit of the photoreaction centre of Rhodopseudomonas viridis enhance murine splenocyte proliferation. J Pept Sci 1995, 1(3):184-190.
40. Keler T., Ramakrishna V., Fanger M.W. Mannose receptor-targeted vaccines. Expert Opin Biol Ther 2004, 4(12):1953-1962.
41. Copland M.J., Baird M.A., Rades T., McKenzie J.L., Becker B., Reck F., et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003, 21(9-10):883-890.